Amneal Pharmaceuticals, Inc. (AMRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 14/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.32% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
- 3 Overrated Stocks We Think Twice About
- Amneal to Report Third Quarter 2026 Results on November 3, 2026
- 3 Low-Volatility Stocks with Open Questions
- Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches
- Why Is Amneal (AMRX) Stock Rocketing Higher Today
- Amneal Announces FDA Approval and Launch of Lanreotide Injection
- 3 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Amneal Pharmaceuticals, Inc..
Full AMRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.